Our environmental protection journey

Ambition Zero Carbon towards a restorative approach

2030
- Carbon negative across our value chain

2025
- Zero carbon emissions in our operations
- Launch near-zero Global Warming Potential inhaler propellants
- 50 million trees planted

2020 and beyond

2019
Confirming our climate action targets are on track
Science Based Targets Initiative (SBTi) confirms that our carbon targets meet Paris Agreement's 1.5 degree scenario guidance

2016
Setting 2015–2025 targets
Commitments to double environmental efficiency with new energy, water and waste targets

Carbon targets approved by the Science Based Targets initiative (SBTi)

Commitments for Product environmental stewardship and PIE management

RE100 goal to source 100% renewable electricity by 2025

GHG **36%** reduction in scope 1 and 2 GHG emissions since 2015

WATER **18%** reduction in water use since 2015

GHG **62%** total electricity from renewables in 2019

WASTE **11%** increase in waste since 2015

2014
Seeking external perspectives
Creation of Environmental Advisory Board with external experts (in 2015 evolved into our Sustainability Advisory Board)

WASTE **18%** reduction in total waste generated since 2010

GHG **21%** reduction in operational GHG emissions (excluding inhaler usage) since 2010

WATER **14%** reduction in water use since 2010

2011
Supporting suppliers to implement more robust environmental practice
First company to have an active pharmaceutical ingredient (API) discharge programme for suppliers

GHG **9%** reduction in GHG emissions since 2006

WASTE **40%** reduction in total waste relative to sales since 2006

2001
Greater transparency
First public reporting of environmental data and first companywide environmental target set

Launched a tool for integrating SHE matters into medicine development

2005
Greener chemistry in our processes
Founding member of American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable

CFC **42%** reduction in emission of ozone depleting substances since 2002

WASTE **32%** reduction in waste relative to sales since 2002

2008
Considering the environment alongside drug discovery
Environmental Risk Management Plans are introduced to accompany new medicines along the path to launch, providing early warning of medicines that could pose a potential risk to the environment

2010
Reducing our contribution to ozone layer depletion
Elimination of ozone damaging chlorofluorocarbons (CFCs) from our inhalers